Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2013 | Original Article

Diuretic ¹⁸F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique

Authors: Brusabhanu Nayak, Prem Nath Dogra, Niraj Naswa, Rakesh Kumar

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2013

Abstract

Purpose

Positron emission tomography/computed tomography (PET/CT) with ¹⁸F-fluorodeoxyglucose (FDG) has been used with limited success in the past in primary diagnosis and locoregional staging of urinary bladder cancer, mainly because of the pharmacokinetics of renal excretion of ¹⁸F-FDG. In the present prospective study, we have evaluated the potential application of diuretic ¹⁸F-FDG PET/CT in improving detection and locoregional staging of urinary bladder tumours.

Methods

Twenty-five patients suspected of having primary carcinoma of the urinary bladder were evaluated prospectively for diagnosis and staging. All of these 25 patients underwent conventional contrast-enhanced computed tomography (CECT) of the abdomen/pelvis and whole-body diuretic ¹⁸F-FDG PET/CT. In addition, pelvic PET/CT images were obtained using the special technique of forced diuresis using intravenous furosemide (20–40 mg). Of the 25 patients, 10 underwent radical cystectomy and 15 underwent transurethral resection of the bladder tumour (TURBT). Results of CECT and diuretic ¹⁸F-FDG PET/CT were compared considering histopathology as a reference standard.

Results

Of the 25 patients, CECT detected a primary tumour in 23 (sensitivity 92 %), while ¹⁸F-FDG PET/CT was positive in 24 patients (sensitivity 96 %). Mean size and maximum standardized uptake value of the bladder tumours were 3.33 cm (range 1.6–6.2) and 5.3 (range 1.3–11.7), respectively. Of the 25 patients, only 10 patients underwent radical cystectomy based on disease status on TURBT. Among those ten patients, nine had locoregional metastases. Among the nine patients who had positive lymph nodes for metastasis on histopathology, CECT and PET/CT scan had a sensitivity of 44 and 78 %, respectively. ¹⁸F-FDG PET/CT was found to be superior to CECT in the detection of the primary tumour and locoregional staging (p < 0.05).

Conclusion

Diuretic ¹⁸F-FDG PET/CT is highly sensitive and specific and plays an important role in improving detection of the primary tumour and locoregional staging of urinary bladder tumours. Diuretic ¹⁸F-FDG PET/CT demonstrated a higher diagnostic value when compared with CECT in these patients.

Carroll PR. Urothelial carcinoma: cancers of the bladder, ureter, and renal pelvis. In: Tanagho EA, McAninch JW, editors. Smith’s general urology. 15th ed. New York: McGraw-Hill; 2000.

Wong-You-Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA. From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation. Radiographics 2006;26:553–80.PubMedCrossRef

Kim JK, Park SY, Ahn HJ, Kim CS, Cho KS. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004;231(3):725–31.PubMedCrossRef

Knox MK, Cowan NC, Rivers-Bowerman MD, Turney BW. Evaluation of multidetector computed tomography urography and ultrasonography for diagnosing bladder cancer. Clin Radiol 2008;63(12):1317–25.PubMedCrossRef

Husband JE. Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. J Belge Radiol 1995;78(6):350–5.PubMed

Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193(1):239–45.PubMed

Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009;27(26):4314–20.PubMedCrossRef

Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010;28(25):3973–8.PubMedCrossRef

Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32(12):1412–7.PubMedCrossRef

10.

Anjos DA, Etchebehere ECSC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48(5):764–70.PubMedCrossRef

11.

Voges GE, Tauschke E, Stöckle M, Alken P, Hohenfellner R. Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol 1989;142(4):972–4.PubMed

12.

Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000;163(6):1693–6.PubMedCrossRef

13.

Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, et al. Uptake of 2-deoxy 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991;145(2):279–83.PubMed

14.

Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34(4):274–92.PubMedCrossRef

15.

Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010;57(4):641–7.PubMedCrossRef

16.

Kamel EM, Jichlinski P, Prior JO, Meuwly JY, Delaloye JF, Vaucher L, et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 2006;47(11):1803–7.PubMed

17.

Tekes A, Kamel IR, Imam K, Chan TY, Schoenberg MP, Bluemke DA. MR imaging features of transitional cell carcinoma of the urinary bladder. AJR Am J Roentgenol 2003;180(3):771–7.PubMed

18.

Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005;46(11):1819–24.PubMed

19.

Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007;32(2):101–5.PubMedCrossRef

Title: Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique
Authors: Brusabhanu Nayak
Prem Nath Dogra
Niraj Naswa
Rakesh Kumar
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2294-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diuretic ¹⁸F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI?

FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach

Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide

Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours